Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

被引:116
作者
Harms, DO [1 ]
Janka-Schaub, GE [1 ]
机构
[1] Childrens Univ Hosp, Dept Hematol & Oncol, D-20246 Hamburg, Germany
关键词
childhood; lymphoblastic leukemia; outcome; CNS control;
D O I
10.1038/sj.leu.2401974
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The German Go-operative Study Group COALL far treatment of acute lymphoblastic leukemia (ALL) in childhood started the first trial in 1980. This report gives an overview of the long-term results of the four consecutive studies COALL-82, COALL-85, COALL-89 and COALL-92. Besides improvement in long-term survival major objectives were reduction of treatment-related toxicity by transferring asparaginase (ASP) from induction therapy to intensive phase and omitting CNS irradiation by stepwise increase of the initial white blood count (WBC) up to 50 x 10(9)/1 (exception T-ALL) as criterion for irradiation. In study COALL-85 in high risk patients slow vs rapid rotational treatment was randomized. In study COALL-92 initial response to daunorubicin (DNR) as a l-h vs 24-h infusion and its prognostic value was investigated. Furthermore, g-mercaptopurine (6-MP) and B-thioguanine (6-TG) were randomized in maintenance treatment. In total, 1191 eligible patients were enrolled. Induction treatment without ASP has been shown to be as effective and less hazardous than the former four-drug induction. CNS control could be obtained in most without cranial irradiation (CNS relapse-free survival >95%). The leukemic cell kill with a 24-h DNR infusion was equivalent to that of a l-h infusion. DNR response was of less prognostic significance than prednisone response. The rapid rotation regimen failed to improve outcome as well as 6-TG in maintenance treatment. However, intensification of systemic treatment resulted in an increase in overall event-free survival (EFS) to approximately 80% which is comparable to other groups.
引用
收藏
页码:2234 / 2239
页数:6
相关论文
共 13 条
[1]  
COX DR, 1972, J R STAT SOC B, V34, P187
[2]   Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine [J].
Erb, N ;
Harms, DO ;
Janka-Schaub, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) :266-272
[3]  
HARMS D, 1994, MED PEDIATR ONCOL, V23, P197
[4]  
Janka G E, 1987, Haematol Blood Transfus, V30, P456
[5]   ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD - THE COALL THERAPY STUDIES [J].
JANKA, GE ;
WINKLER, K ;
JURGENS, H ;
GOBEL, U ;
GUTJAHR, P ;
SPAAR, HJ .
KLINISCHE PADIATRIE, 1986, 198 (03) :171-177
[6]  
JANKA GE, 1999, MED PEDIATR ONCOL, V33, P217
[7]  
JUERGENS H, 1992, HAEMATOL BLOODTRANSF, V34, P338
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   THE INVIVO RESPONSE ON CORTICOSTEROID-THERAPY AS AN ADDITIONAL PROGNOSTIC FACTOR IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA (THERAPY STUDY ALL-BFM 83) [J].
RIEHM, H ;
REITER, A ;
SCHRAPPE, M ;
BERTHOLD, F ;
DOPFER, R ;
GEREIN, V ;
LUDWIG, R ;
RITTER, J ;
STOLLMANN, B ;
HENZE, G .
KLINISCHE PADIATRIE, 1987, 199 (03) :151-160
[10]  
SCHAUB GEJ, 1988, KLIN PADIATR, V200, P171